1 Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure
S.M. Bruinsma, M.J. Roobol, P.R. Carroll, L. Klotz, T. Pickles, C.M. Moore, V.J. Gnanapragasam, A. Villers, A. Rannikko, R. Valdagni, M. Frydenberg, Y. Kakehi, C.P. Filson, C.H. Bangma, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
Nature Reviews Urology 2017, 14 (5): 312-322
PubMed: 28290462
2 The Movember Foundation's GAP3 cohort: A profile of the largest global prostate cancer active surveillance database to date
S.M. Bruinsma, L. Zhang, M.J. Roobol, C.H. Bangma, E.W. Steyerberg, D. Nieboer, M. Van Hemelrijck, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
BJU International 2018, 121 (5): 737-744
PubMed: 29247473
3 Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies
T.H. van der Kwast, J. Helleman, D. Nieboer, S.M. Bruinsma, M.J. Roobol, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
European Urology Oncology 2019, 2 (3)
PubMed: 31200849
4 Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
M. van Hemelrijck, X. Ji, J. Helleman, M.J. Roobol, W. van der Linden, D. Nieboer, C.H. Bangma, M. Frydenberg, A. Rannikko, L.S. Lee, V.J. Gnanapragasami, M.W. Kattan, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
European Urology 2019, 75 (3): 523-531
PubMed: 30385049
5 Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts
F.-J. H. Drost, D. Nieboer, T.M. Morgan, P.R. Carroll, M.J. Roobol, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
European Urology 2019, 76 (5): 693-702
PubMed: 31451332
6 Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative
A.A. Kalaparaa, J.F.M. Verbeek, D. Nieboer, M. Fahey, V. Gnanapragasam, M. Van Hemelrijck, L.S. Lee, C.H. Bangma, E.W. Steyerberg, T. Harkin, J. Helleman, M.J. Roobol, M. Frydenberg, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
European Urology Oncology 2020, 3 (1), 80-91
PubMed: 31564531
7 Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients
A. Tomer, D. Nieboer, M.J. Roobol, A. Bjartell, E.W. Steyerberg, D. Rizopoulos, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
BJU International 2021, 127: 96-107
PubMed: 32531869
8 Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies
W. Li, B.T. Denton, D. Nieboer, M.J. Roobol, T.M. Morgan, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
Cancer Medicine 2021, 127: 96-107
PubMed: 33159431
9 Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative
S.M. Bruinsma, D. Nieboer, M.J. Roobol, C.H. Bangma, J.F.M. Verbeek, V. Gnanapragasam, M. van Hemelrijck, M. Frydenberg, L.-S. Lee, R. Valdagni, C. Logothetis, E.W. Steyerberg, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
Journal of Urology 2021, 206 (1): 62-68
PubMed: 33617330
10 A first step towards a global nomogram to predict disease progression for men on active surveillance
M. van Hemelrijck, X. Ji, J. Helleman, M.J. Roobol, D. Nieboer, C.H. Bangma, M. Frydenberg, A. Rannikko, L.S. Lee, V. Gnanapragasam, M.W. Kattan, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
Translational Andrology and Urology 2021, 10 (3): 1102-1109
PubMed: 33850745
11 Using the Movember Foundation’s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual function - a retrospective study in low-risk prostate cancer patients
R.T. Crump, S. Remmers, M. van Hemelrijck, J. Helleman, D. Nieboer, M.J. Roobol, L.D.F. Venderbos, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
Translational Andrology and Urology 2021, 10 (6): 2719-2727
PubMed: 34295757
12 Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
K. Beckmann, A. Santaolalla, J. Helleman, P. Carroll, B.H. Chung, L.S. Lee, A. Perry, J. Rubio-Briones, M. Sugimoto, B. Trock, R. Valdagni, P. Dasgupta, M. Van Hemelrijck, O. Elhage, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
European Urology Open Science 2021, 34 (Suppl 1): 47-54
PubMed: 34934967
13 Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
J. Olivier, W. Li, D. Nieboer, J. Helleman, M.J. Roobol, V. Gnanapragasam, M. Frydenberg, M. Sugimoto, P. Carroll, T.M. Morgan, R. Valdagni, J. Rubio-Briones, G. Robert, P. Stricker, A. Hayen, I. Schoots, M. Haider, C.M. Moore, B. Denton, A. Villers, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
European Urology Open Science 2022, 35: 59–67
PubMed: 35024633
14 Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database
K. Beckmann, C.H. Bangma, J. Helleman, A. Bjartell, P.R. Carroll, T. Morgan, D. Nieboer, A. Santaolalla, B.J. Trock, R. Valdagni, M.J. Roobol, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium
Prostate 2022, 82 (7): 876-879
PubMed: 35254666
15 Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
S. Remmers, J. Helleman, D. Nieboer, B. Trock, M.E. Hyndman, C.M. Moore, V. Gnanapragasam, L.S. Lee, O. Elhage, L. Klotz, P. Carroll, T. Pickles, A. Bjartell, G. Robert, M. Frydenberg, M. Sugimoto, B. Ehdaie, T.M. Morgan, J. Rubio-Briones, A. Semjonow, C.H. Bangma, M.J. Roobol, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
European Urology Open Science 2022, 41: 126–133
PubMed: 35813247
16 Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort
C. Marenghi, Z. Qiu, J. Helleman, D. Nieboer, J. Rubio-Briones, P.R. Carroll, L.S. Lee, R. Valdagni, P.C. Boutros, N. Nicolai, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
Cancers 2022, 14 (15): 3558
PubMed: 35892817
17 Risk of progression following a negative biopsy in prostate cancer active surveillance
K. Beckmann, A. Santaolalla, M. Sugimoto, P. Carroll, J. Rubio, A. Villers, A. Bjartell, T. Morgan, P. Dasgupta, M. Van Hemelrijck, O. Elhage, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
Prostate Cancer and Prostatic Diseases 2022, ?? (??): ??
PubMed: 36008540